Loading insider details...
Beta
Latest Form 4 (Jul 8, 2026): Sale of 4,111 ELVN shares, $205.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 8, 2026 | Enliven Therapeutics, Inc. (ELVN) | Sale | 4,111 | $205.5K |
| Jun 9, 2026 | Enliven Therapeutics, Inc. (ELVN) | Sale | 7,779 | $266.7K |
| Feb 18, 2026 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 17,126 | n/a |
| Jan 6, 2026 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/Award | 40,000 | n/a |
| Dec 19, 2025 | Enliven Therapeutics, Inc. (ELVN) | Exercise/Conversion | 15,958 | $17.9K |
| Dec 9, 2025 | Oric Pharmaceuticals, Inc. (ORIC) | Exercise/Conversion | 10,000 | $79.0K |
| Dec 5, 2025 | Oric Pharmaceuticals, Inc. (ORIC) | Exercise/Conversion | 5,534 | $20.8K |
| May 19, 2025 | Nurix Therapeutics, Inc. (NRIX) | Grant/Award | 25,000 | n/a |
| Mar 4, 2025 | Oric Pharmaceuticals, Inc. (ORIC) | Exercise/Conversion | 27,666 | $103.7K |
| Feb 10, 2025 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 15,368 | n/a |